Showing posts with label TOOAJ. Show all posts
Showing posts with label TOOAJ. Show all posts

Wednesday, 30 August 2023

Lupine Publishers | Neural Mechanisms and Causes of Non-Traumatic and Non- Pathological Strabismus. Comparison of Vision Therapy Programmes - A Systematic Review

 Lupine Publishers | Journal of Trends in Ophthalmology


Abstract

Purpose: This study’s aim is to explore the various neural mechanisms and possible causes of strabismus, review vision therapy programmes suggested by different authors and observe potential variations of the aforementioned programmes in adults and children.

Methods: A search was conducted using various scientific databases and other sources. The risk of bias of the included articles was evaluated using the SYRCLE for animal studies, the ROBINS-I and the JBI tool for case reports.

Results: The search showed a total number of 28789 articles. After excluding irrelevant to this research articles, the final reviewed studies are 34.

Conclusion: Strabismus alters various brain areas the neural synapses and connections of which are affected. Numerous vision therapy procedures are recommended by the referenced authors while different programmes are applied in children and adults

Introduction

Strabismus is a misalignment of the eyes usually characterised by loss of binocular fusion. Depending on the severity and the age of onset it may co-exist with suppression, normal or abnormal retinal correspondence, poor or no stereopsis, reduced eye movements, nystagmus and amblyopia. However, the mechanisms and causes of strabismus remain under investigation. The reason for this is because strabismus is a condition that presents a multifarious and multi-level complexity. The visual system develops early in life. The first four to six postnatal months of age are crucial for the development of binocular fusion and stereopsis. As Katz and Shatz accurately observe, “the connection of the visual system is initially based on the formation of synapses which are controlled by molecular guidance cues” [1]. Moreover, Zhang, Poo, Kirkby and others correctly state that “when various stimuli by activity is received, the neural circuit starts to develop and coordinate [2], forming a local network of interactions within the cortex” [3]. The visual cortex (V1) is organized in columns of neurons coming from the lateral geniculate nucleus (LGN). Each column is driven by a dominant eye (namely the right or the left eye) [4]. Katz and Shatz interestingly suggest that “in early months of life these columns are absent in layer 4 (V1) which is responsible for binocular sensory fusion and stereopsis. Early visual activity and stimuli trigger anatomical rearrangements in the synaptic physiology of layer 4 neurons which are activated by both eyes and finally each formed column responds to one eye stimulus only” [1]. These signals from the left and right eye join in V1 and form neurons of binocularity in layer 4 which are essential for sensory fusion. A specific part of V1 and V2 neurons, are sensitive to relative disparity of a visual target or elements of a visual scenery and are responsible for stereopsis [5]. Consequently, it appears that visual disparity and eye alignment are closely intertwined. More precisely, the interruption of this interaction between visual disparity and eye alignment might be attributed as one of the causes of strabismus which is produced by abnormal sensory experiences early in life. Additionally, sensory fusion and stereopsis and a combination of binocular disparity of visual signals and accommodative response due to closeness of the visual target, drive the extraocular muscles of the eyes to change their angle. When the binocular system is developed normally the eye movements are precise and coordinated, while a disruption of the development of binocular fusion leads to poor stereopsis and motor guidance of the extraocular muscles and is associated with strabismus and suppression. The absence of sensory fusion and the abnormal development of binocular neurons of disparity, will eventually lead to the loss of critical error signals in the cortex or the brain stem, necessary for the orthoptic alignment and development of the eyes [5]. This may result in poor visual activity and stimuli in the early months of life. Moreover, this condition once developed may further lead to false calibration of the neural circuits and connections in multiple levels from the visual cortex to the motor neurons. The sensitivity of the binocular vision neurons and the binocular motor coordination of the eyes are connected with the level of development of the visual system through relevant visual experience in early stages of an individual’s life. This observation implies that the interruption of binocular vision encountered at an early age may lead to strabismus. The degree that the visual and visuomotor function may be influenced, due to the aforementioned early abnormal visual experience, depends largely on the age of onset, the duration and the type of interruption [5]. As a result, the ocular dominant columns in layer 4 of the visual cortex which develop through the visual input of each eye separately will be unavoidably affected. The following example, retrieved from Tychsen’s study, may frame better the said issue. In strabismic monkeys the binocular connections in the ocular dominant columns dropped by 50%, whereas the monocular ones were preserved. Yet, the ocular dominant columns of the strabismic eye were considerably less than in the non- strabismic one. The remained connections spurred abnormal and inhibitory reactions causing suppression in every row of columns which corresponded to the strabismic eye [4] Conventional treatments of strabismus include, inter alia, full prescription glasses in the case of accommodative esotropia, patching, penalisation using atropine drops or Bangerter filters if strabismus co-exists with amblyopia and surgery. Modern treatment methods developed in the last century are based on active vision therapy which focuses on the binocular function. More precisely, these methods aim to re- train the brain regarding the way it uses the two eyes together. Vision therapy varies from simple to complicated tasks and also incorporates different techniques and sensory integration. These techniques not only require the active effort and contribution of the eyes, but also the body movement and balance involvement. The equipment that is usually used includes inter alia: stereoscopes, Brock string, Hart charts, tranaglyphs, vectograms, Marsden ball, rotator, aperture rule, red/green filters, polarized and red-green reading bars, tachitoscope, fusion targets, prisms, lenses and other filters. Vision therapy’s core philosophy takes advantage of the neuroplasticity of the brain. This means that the brain has the extraordinary ability to continuously learn, improve and adjust to the specific existing surrounding conditions regarding the use of the two eyes together by forming new neurological pathways and synapses, establishing, internalising and generating new skills. Depending on the age and the severity of the problem, applied vision therapy has indeed demonstrated outstanding results in various cases of binocular vision dysfunctions. Strabismus is one of the binocular vision dysfunctions that vision therapy may be applied effectively, demonstrating satisfying and even exceptional results without the need for any surgical intervention. The way vision therapy makes this possible, is a rather interesting procedure. As already discussed, vision therapy’s main concept is based on the neural plasticity of the brain. The said plasticity of the visual system develops until the age of 9. Thus, greater positive results may be achieved through active vision therapy especially within this timeframe, namely from birth until the first 9 years of a child’s life. This is because the cells in the lateral geniculate nucleus and the visual cortex “die” after the age of 9, because of the lack of stimulation [6]. This does not mean that vision therapy in adults is not effective, but it may require longer periods of time and more intense efforts to achieve the desired results. Moreover, the said difficulty may discourage the individual from continuing the participation of the treatment, if the individual has established and internalised the visual dysfunction with habitual visual patterns. Depending on the severity of the problem, namely how deep the issue is established and whether the individual is aware or not of these habitual patterns, it may be close to impossible to “break” and “erase” the said patterns. An example of such a difficulty that will undoubtedly hinder vision therapy treatment applicability and results, is the existence of an adult patient who is diagnosed with alternating exotropia, visual acuity OU: 10/10, abnormal retinal correspondence (ARC), suppression and complete absence of Randot stereo fusion. In this type of strabismus it may be extremely difficult to “break” the alternate fixation patterns along with the ARC pattern. This also depends on how much embedded these patterns are in a patient’s visual framework and whether the individual is aware of them or not. For example, in the possible case of a strabismic adult patient who is not aware of the habitual visual patterns embedded into the strabismus problem, a vision therapy treatment plan may have a minimal effect on eliminating the said patterns. Needless to say, each case is unique, which implies that the success of a vision therapy programme depends not only on the optometrist’s expertise and experience, but also on the patient’s persistence, constant focus and determination to follow the instructions and guidance of the optometrist.

-According to Press [6]: In children, the expansion of binocular awareness and the cosmetic improvement of a strabismic deviation outweigh the relatively minor alteration in habitual vision. As a patient lives with his strabismus longer, and the adaptation builds, the elimination of the strabismus may be perceived as a tradeoff. An example is a patient with divergence excess exotropia who panoramically views at distance. This patient essentially enjoys the benefits of having a “picture within a picture” television screen. He has learned how to divide his attention - split the screen, so to speak - so that the fixating eye watches the main programme centrally, while the exotropic eye views a peripheral station. At the moment he aligns his eyes, he feels cheated out of one picture. Before commencing a vision therapy (VT) programme, a complete behavioral and functional visual examination is necessary in which not only the characteristics of the visual system are evaluated in an analytical way, but also the use of the visual system through observation of the patient’s behavior.

According to Vidal-López, 2018, [7] as depicted in p. 93, it is important to classify the strabismus by:

a) Age of onset: congenital if it occurs between birth and 6 months of age and early onset strabismus between 6 and 36 months of age.

b) Constancy: constant when the strabismus is always observed, intermittent when the condition is observed occasionally and accommodative when the accommodation is the primary cause of the squint.

c) Localisation: in distance and near vision.

d) Laterality: unilateral, when only one eye deviates, alternating, when the strabismus occurs in both eyes.

e) Directionality: horizontal, esotropia, if the eye turns nasally, exotropia, if the eye turns temporally. Vertical hypertropia when the eye turns upwards and hypotropia when the eye turns downwards. Rotational, incyclotropia and excyclotropia.

f) Magnitude: microtropia below 4 Δ, small-angle strabismus from 4 Δ to 9 Δ, moderate-angle strabismus from 10 Δ to 30 Δ and large-angle strabismus more than 30 Δ.

g) Correspondence: if the retinal correspondence is normal or abnormal. If it is abnormal, is it harmonious to the deviation angle or unharmonious.

h) Concomitance: concomitant strabismus is present when the angle of deviation does not vary more than 5 Δ in any gaze position. Non-concomitance is present when the angle of deviation varies in different gaze positions.

i) Organic origin: if the strabismus is related to a disease or syndrome if it is functional or not.

According to Von Noorden, 1988, [25] a successful therapy on strabismus needs to meet the following criteria:

a. Incomplete binocular vision: Which is characterised by orthotropia or eterophoria without symptoms, normal visual acuity in eyes, peripheral identification, normal retinal correspondence, central scotoma in one eye and low or absence of stereopsis. This outcome is the best possible.

b. Microtropia: small or absence of movement in cover test, possible mild amblyopia, peripheral identification, abnormal retinal correspondence and low or absence of stereopsis.

c. Small-angle strabismus (<20 Δ): this deviation is acceptable, with abnormal retinal correspondence, low or absent stereopsis.

d. Large-angle strabismus (>20 Δ): this deviation is noticeably obvious. Suppression is present and stereopsis is absent.

Van Noorden studied the results of strabismus surgery in infantile esotropia and assessed which outcomes could be considered as “successful” and whether this evaluation could be characterised as subjective, since the alignment of the eyes surgically does not necessarily enhance the binocular fusion of the brain. In fact, there is no intervention post surgically to stimulate the fusion and stereopsis of the brain. Instead, the visual system shall regain fusion and stereopsis by itself with no further stimulation intervention which leads to very low or even no results of such regainment. On the contrary, active vision therapy brings the two foveae together and re-aligns the eyes with the visual axis by enhancing binocular fusion and stereopsis and providing the necessary stimulation, so that the brain can rebuild neural synapses of binocularity in the visual cortex. Having set the pace for the analysis of this paper, the aim and structure of this work will be presented briefly. The aim of this review is to gather scientific literature about the neural mechanisms and potential causes of nontraumatic and pathological strabismus and the changes that occur in the visual cortex. Also, different approaches of vision therapy programmes set forth by different authors in strabismic cases will be critically observed aiming to evaluate whether any variances between treating children and adults exist. To this end, a systematic review is performed based on bibliography and internet search databases. Both tools are used to search for scientific evidence, possible explanations regarding the neural origins of strabismus, experiments in animals with induced strabismus and case studies and reports in the field of vision therapy treatment of strabismus.

Objectives

Many reviews, research papers and studies have been conducted by ophthalmologists and optometrists analysing the “peripheral” origins of strabismus related to abnormalities of muscles and pulleys of the eyes that affect the oculomotor system. Many cases of strabismus are indeed associated with syndromes and oculomotor dysfunctions, nevertheless little is known about the “central’’ roots of strabismus. So far, the research on central roots examines the potential neural changes and alterations of the binocular circuit and acknowledge that an abnormal neural signal is the effect of false input to the muscles and pulleys of the eyes, rather than the cause [8]. Similarly, more weight has been placed on the well- established approach in the methods of strabismus treatment, rather than vision therapy. Specifically, extensive studies regarding the efficacy and results of strabismus surgery and the use of pharmaceutical substances, such as the Botulinum toxin have been thoroughly investigated and little is known about other methods of intervention, such as vision therapy. Respectively, although a considerable quantity of scientific data is available on the effects of vision therapy in different visual dysfunctions such as convergence insufficiency, still a finite number of reviews are dealing with the vision therapy treatment programmes in various strabismic cases. Hence, the available literature about vision therapy strabismus plans written by different optometrists for adults and children is limited. It follows from the above that VT,being an alternative treatment of strabismus, is a field “under investigation”. To this end, this review will contribute through the gathering of available literature and bibliographic information on the analysis of the following topics: i) the potential neural causes and mechanisms of strabismus, ii) how different authors propose different vision therapy programmes in various strabismic cases and iii) the difference in approach to vision therapy treatment procedures for adults and children. The whole aim of this thesis is to provide specific information to a wider audience in the scientific community.

Methods

For the purposes of this review, a search was conducted on the scientific databases of PubMed, FrontiersIn, Plos One, Science Direct, and Journal of Neurophysiology. Further sources also include the OEPF (Optometric Extension Program Foundation), the COVD (College of Optometrists in Vision Development) and the E-Cronicon websites. Regarding the first five databases, the research was conducted using key research words and phrases that are presented in Table 1, describing with specific vocabulary the subject of the investigation. The search conducted on the OEPF website was focused on the Journal of Behavioral Optometry which revealed relevant articles in Volume 15 – Issue 1 – “Optometric Management of Patients with Incomitant Strabismus”, written by David L. Cook O.D. and Volume 13 – Issue 2 – “The Interface between Ophthalmology and Optometric Vision Therapy”, written by Leonard J. Press O.D. Although the title of the latter article does not match the subject of this review, further information on methods of optometric vision therapy is covered in Table 7 of the appendix section. The information of the said article is presented in a sequential and methodological plan for the strabismus vision therapy and this is why this article was considered relevant for the purposes of this paper. Furthermore, additional studies and reviews regarding the efficacy of VT, sequential plans of treatment and results of therapy in various forms of strabismus were retrieved from the COVD website. The said studies include and present the expertise of different authors who approached strabismus therapy on an ad hoc basis, namely according to the history of the patient, the age of onset and the diagnostic results of the patient. The titles, abstracts and citation information of the COVD studies are available on the “Summary of Research and Clinical Studies on Optometric Vision Therapy” document using the search engine of the website and typing the phrase “summary of research on optometric vision therapy”. The studies were looked up on PubMed database for further review and availability status.

However, the full text of a considerable number of studies was not available for review due to the absence of DOI number which is essential in tracking the full text. Last but not least, the review of “The Power of Effective Vision Therapy” written by Joseph Pederzolli in 2019 was specifically searched on E-Cronicon. The “Origins of Strabismus and loss of binocular vision” written by Emmanuel Bui Quoc and Chantal Milleret published on 25th September 2014 found in Frontiers In integrative neuroscience Volume 8 – Article 71, formed the basis for further search of the neural mechanisms and causes of strabismus, and for tracking other relevant studies in the reference section. Additionally, another article that included a rich section of relevant references on strabismus is the “Neural mechanisms of oculomotor abnormalities in the infantile strabismus syndrome” written by Mark M.G. Walton, Adam Pallus, Jérome Fleuriet, Michael J. Mustari and Kristina Tarczy-Hornoch, published on 10th April 2017 by J Neurophysiol. The references section of other studies was also utilised to pinpoint experiments in cats and monkeys with induced strabismus and changes in their visual cortex, the neural wiring of retinal waves in mice and the development of the visual brain and to supplement information on the changes that occur in V1 and V2 and how other sections of the brain controlling the oculomotor movements are affected. As mentioned before, the research found on vision therapy was limited to reviews on its efficacy in strabismus, the role of vision therapy in various forms of strabismic cases, orthoptics programmes and a few vision therapy case studies and reports on adults and children. All studies reviewed and included herein were written in the English language. No other limitations were imposed with regards to the eligibility criteria in the year of publication, publication status and length. It should be noted that a number of studies were reviewed, however only a few were selected for the purposes of this review according to the following criteria:

Table 1: words and phrases used in search databases.

Lupinepublishers-openaccess-Ophthalmology

Table 2: Results of JBI tool for case reports.

Lupinepublishers-openaccess-Ophthalmology

Table 3: Results of SYRCLE tool for animal studies.

Lupinepublishers-openaccess-Ophthalmology

Table 4: Results of ROBINS-I tool for risk of bias assessment.

Lupinepublishers-openaccess-Ophthalmology

Table 5: Excluded articles in the systematic review.

Lupinepublishers-openaccess-Ophthalmology

a. Articles referring to strabismus the aim of which is to explain the possible neurological changes in the visual pathway and the visual cortex, the oculomotor abnormalities and the changes in the brain areas that control the eye movements, the role of uncorrelated binocular input in strabismus, the loss of binocular fusion and stereopsis, the neural basis of suppression and strabismic amblyopia, the early development of the visual system and the interconnections to various cortexes and the development of binocular fusion and stereopsis.

b. Articles referring to induced experimental strabismus in animals aim to explain the modifications of the visual cortex connections, neural deficits, deficits in the synapses of binocular fusion and stereopsis and neural correlations.

c. Articles describing the characteristics of suppression and anomalous retinal correspondence and their clinical assessment.

d. Articles referring to vision therapy and orthoptics which describe treatment procedures and sequential plans, the efficacy of therapy in various forms of strabismus and case studies and reports in children and adults.

As far as the aforementioned selection criteria of articles and case studies is concerned, the following observations shall be noted. Firstly, the titles and abstracts were reviewed in order to exclude irrelevant subjects of investigation. Secondly, duplicates in studies which shared the same citation, same author(s), title, publication date, volume and issue were omitted. Thirdly, the complete texts of the remaining reviews were studied in order to assess and select the ones that complied with the aforementioned criteria and research pursuits of this study. Articles describing traumatic, pathological, accommodative, muscle, pulley and syndrome related causes of strabismus, the surgical intervention in muscles and pulleys of the eyes, the use of toxins, pharmacological preparations and patching methods in cases of strabismic amblyopia, were excluded. The only exception in patching as a method of intervention is the use of Bangerter filters and binasal occlusion combined with vision therapy techniques. The reason for this is that Bangerter filters enhance binocularity and contrast sensitivity in amblyopic cases, whereas binasal occlusion enhances peripheral fusion of the retina which in combination with vision therapy activities will contribute to the eye alignment of strabismic cases. An article describing the use of Bangerter filters for amblyopia was excluded because it focused on a different subject. However, a few articles that were included herein describe the use of binasal occlusion combined with vision therapy procedures. The risk of bias assessment was performed in all experimental studies in animals, humans, case studies and reports using specific tools that are described analytically in the Results section. Finally, all included studies were gathered in two separate tables; Table 6 includes the strabismus studies and Table 7 the vision therapy reviews and studies.

Table 6: Strabismus studies analysis review.

Lupinepublishers-openaccess-Ophthalmology

Table 7: Vision Therapy programmes analysis review.

Lupinepublishers-openaccess-Ophthalmology

Results

The total number of search results regarding both strabismus and vision therapy topics were 28,770. As already discussed, a considerable number of these studies were irrelevant to the subject of this review, while many of the results did not meet the aforementioned selection criteria. Therefore, 90 articles were selected. After rejecting 19 duplicates, 71 articles were reviewed based on their titles and abstracts. Finally, 40 of these articles were rejected as being irrelevant to this review. Thus only 31 articles were ultimately deemed as relevant and therefore fully reviewed. Three (3) other relevant articles were retrieved from other sources (OEPF, COVD and E- Cronicon) collecting 34 articles in total for this review. Flowchart 1 presents in a clear manner the process of selection and rejection of articles from both sources. As mentioned, the COVD articles were searched on PubMed database. Eight (8) out of 16 articles were not available and impossible to be found due to the absence of their DOI number. Eight (8) articles were rejected as they did not meet the inclusion criteria and did not provide vision therapy programmes in a descriptive manner. The result is the complete exclusion of the COVD list. Finally, 2 articles retrieved from OEPF and one from E-Cronicon were included, making a total of 3 articles from other sources. Consequently, the final number of articles included in this review from both sources is 34.

Various risk of bias tools were utilised for the analysis of nonrandom studies describing the participation of individual patients, animals and humans. In the context of risk of bias assessment, Table 3 sets out studies of intervention based on experiments on animals with induced strabismus and the SYRCLE risk of bias tool for animal studies. Also, the ROBINS-I risk of bias tool was useful in assessing the risk of bias in non-random studies of intervention in humans. The results of this assessment can be found in Table 4. Furthermore, vision therapy case reports including one patient were evaluated for potential risk of bias according to the JBI tool for case reports presented in Table 2. Generally, the risk of bias assessment performance revealed that the relevant risk of the reviewed studies is rather low, since animal selection, housing and intervention criteria were carefully considered. The potential intervention bias of the scientists is also low; and the scientists who conducted the study were surprised about cases where the outcome of their study differed from their hypothesis. The same was observed in non-random human studies, case studies and reports. The summary Tables 6 and 7 in the appendix section present the participants, the diagnosis, the main conclusions and interventions of the reviewed studies the subject of which is vision therapy and strabismus respectively. Notably, a meta- analysis was not possible, because many studies measured different data: a great number in animals and few in humans, while a number of studies did not mention any relative risk values; thus, it was deemed appropriate for the review results to be presented in Tables 6 and 7 in the appendices section. To be more precise regarding the collection of data from the reviewed studies, Table 6 summarises the ones that focus on strabismus experiments, reviews of literature data, literature reviews containing information about the development of visual brain and articles describing the changes in synapses of neurons and the neuroplasticity of the brain. What is more, Table 7 summarizes all studies found in vision therapy programmes of strabismus treatment written by different authors.

Specifically, Table 7 includes the author, the participant(s), the diagnosis that was identified and further factors to consider which supplements the diagnosis data. Furthermore, the “Factors to Consider” column includes data that significantly influence the vision therapy treatment and results. Factors that potentially facilitate VT efficacy are the following: existence of some degree of fusion, normal retinal correspondence, absence of suppression - although this is a rarely encountered situation - and intermittent exotropia cases with a degree of fusion in specific position of gaze. Factors that potentially complicate and hinder VT effectiveness are the following: absence of fusion, suppression, abnormal retinal correspondence, amblyopia, presence of diplopia and eccentric fixation. In certain reviews the aforementioned abnormalities were presented as a general informative guidance for additional dysfunctions of strabismus and were not assigned to specific cases. Furthermore, the “Missing Data” column of Table 7 includes data that was neither available nor mentioned in the study yet the said data may have played a significant role in the treatment procedures and subsequent results of therapy. Finally, the columns “Office VT programme” and “Home VT programme” sum up the vision therapy protocols proposed by each author and describe the procedures in the office and home therapy.

A considerable number of studies omitted references regarding the significant contribution of home vision therapy activities. The “Applied concepts in vision therapy” book written by Leonard Press provides relevant information on the efficacy of VT treatment in strabismus, yet the book chapters 8 and 16 which were studied for this review do not address any home vision therapy activities. The author states that vision therapy procedures of other visual dysfunctions can be used for the treatment of strabismus without though specifying which procedures could be applied in the context of strabismic cases which are mentioned in Chapter 4 of the book.

Figure 1: Flowchart showing the procedure followed during the systematic review.

Lupinepublishers-openaccess-Ophthalmology

Discussion

According to the results of this systematic review, strabismus affects many areas of an individual’s brain. These areas include inter alia: the lateral geniculate nucleus located in the thalamus which is the principal pathway for visual perception and location [5], the intra-areal connections of V1 and V2 and inter- blob zones found in layers II-III, IV-B, IV-C-α and V located in the visual cortex and receive stimuli activity by orientation, and the velocity and direction of movement [9] and layer 4 in V1 which is responsible for stereopsis. Abnormalities in layer 4 may result in poor or even no stereoscopic vision a result which is characteristic in most forms of strabismus. Additionally, the binocular connections of the ocular dominant columns in the visual cortex are also influenced and reduced whereas the monocular ones are maintained [4]. Moreover, the oculomotor system and the brain centers that control the eye movements are affected as well. These centers are: the superior colliculus in the midbrain which plays a major role in saccadic eye movements, the cerebellum for eye movement control and nystagmus, the extrastriate visual areas in the “dorsal” and “ventral” stream which play a major role in saccadic, pursuit and the vergence eye movements to visual targets and the vestibuloocular reflex which moves the eyes in opposite direction from the head movement [5]. Furthermore, the presence of suppression in strabismus when the two eyes are open appears to relate to altered cortical binocular integration and interocular inhibitory interactions in V1 [10] a result closely associated with past visual experiences and attention of the strabismic subject [11].

The aforementioned areas in the brain are possibly affected simultaneously, depending on the severity of an individual’s condition and the age of onset of the symptoms. Nevertheless, diversity among strabismic cases is present and each case is a unique combination of abnormalities, severity of dysfunctions and affected brain areas. For example, some cases may present fusion capabilities in particular gaze positions, while others sufficient vergence eye movements which can be functional up to a certain point, in a few cases suppression might not be deeply rooted as an inhibitory visual mechanism whereas other cases may not show head and postural imbalance control. Therefore, certain patients may display good diagnostic characteristics which may enable the best possible VT result, whereas other patients may demonstrate severe conditions and abnormalities affecting the efficacy and methods of treatment used in vision therapy. There is one mechanism that is almost always present among the different encountered cases and that is suppression which is not affected by the angle and direction of deviation and, as mentioned before, it may or may not be deeply rooted as an inhibitory mechanism. However, studies have shown that suppression is much stronger in the nasal hemiretina of the esotropic eye [10]. Having mentioned the parameters that affect the severity of strabismus cases, it is equally important to focus on any potential identifiable aspects that enable the normal development of the brain and the changes that are provoked by strabismus while the brain is developing. The binocular synapses of the visual system prenatally are connected, already developed up to a certain point and ready to receive input when the eyes are opened for the first time. The binocular circuitry and cortical networks form and rearrange new synapses, connections and maintain the network by receiving continuous stimuli [3], disparity sensitive error signals which guide the orthoptic eye alignment [5] and molecular guidance cues [12]. When the received stimulus is poor or lost, the connections and synapses are reduced or even obliterated, disparity error messages are absent and eye alignment maintenance is affected, resulting in abnormal signals to the extraocular muscles and ultimately in the misalignment of the eyes. The various possible causes of such an abnormal function between the eyes and the brain, are extensively discussed on the “Origins of strabismus” review, written by Quoc and Milleret in 2014. This review describes in detail a considerable number of possible errors and abnormalities in the visual pathway which pave the way to scientists for additional research towards the understanding of the binocular disruption. However, it remains unknown what happens first; the loss of binocular fusion or the eye misalignment? This is a question that, if answered, will certainly shed light on the main causes of strabismus which will probably make strabismus treatment more specific and hopefully more efficient for both adults and children.

In the meantime, and before answers to the aforementioned questions are justifiably delivered, a promising solution is the exploitation of the brain’s unique capacity of neural plasticity and the exceptional ability of the visual system to create new synapses and connections with proper guidance and stimulation. This is why VT is considered to be a more promising alternative solution to strabismic cases since it is based on the continuous brain activity and its ability to re-build the lost connections and also re-train the brain to keep the orthoptic eye alignment by maintaining sensory and motor memory. This can be enhanced when the stimulation received from the various activities is repetitive up to the point of internalisation and automation. Scientific reviews also present the effect of strabismus in other areas of the brain which may result in abnormal head and body posture, orientation and balance. Consequently, it is logical to combine eye exercises with body, posture, balance, vestibular and orientation exercises. The combination of these exercises features VT as a promising holistic treatment approach of strabismus. The said treatment may result in improving a child’s life when it comes to school performance and other activities, such as sports in which the effective coordination of the eye movements is crucial. To this end as recommended, future research studies may focus on the observation of the brain areas that are affected in strabismus before and after vision therapy by using technological means of brain imaging, such as fMRI and other techniques. The results will most probably show the efficacy of VT treatment compared to other passive treatments, such as surgery, patching in strabismic amblyopia cases and Botinulum toxic use and will provide both information and clarity on the causes and mechanisms that stimulate strabismus as well as the relevant alterations in the brain. As far as the vision therapy study reviews is concerned, a variety of visual therapy programmes is presented in Table 7 describing different cases of eye deviation and concomitant eye dysfunctions, focusing mainly on the application of antisuppression, eye movement, peripheral, monocular fixation in a binocular field (MFBF) and fusion exercises. Each researchertherapist utilises a different sequential protocol of exercises depending on the age of the patient (infant, children or an adult), the age of onset of the problem, the characteristics of the visual system, the diagnosis and the co-existence of further abnormalities that accompany strabismus. The severity of these abnormalities will affect the treatment protocol in VT. Another consideration for the selection of procedures in a VT programme is the patient’s cognitive capacity; for example, a 3-year-old is not ready to read and execute mathematical problems comparing to a 7-year old child. Furthermore, key factors for a successful VT programme are connected with the cooperation of the child in the office treatment, compliance with office and home therapy and willingness of the parents to follow and implement the instructions given by the optometrist. A successful VT programme depends a lot on these parameters and an uncooperative patient makes the treatment process difficult for implementation and leads to uncertain results.

In infants, the therapy is passive focusing on peripheral activation, movement activities including the body, stimulation of labyrinth/proprioceptive and kinesthetic systems, monocular and binocular fixation activities with saccade and pursuit movements using fixation targets that keep the interest of the infant [13]. Stimulation of the vestibular-ocular reflex and post-rotary nystagmus is also a practice that is used in infants according to Bell (2018). In children from 5 to 13 years of age, the standard vision therapy procedures may be implemented along with games and computer orthoptics. However, a vision therapy sequence must be carefully selected as at this age various abnormalities may have been developed and rooted in the visual system such as suppression and abnormal retinal correspondence. If ARC is deeply rooted, a VT programme focusing on antisuppression techniques will not bring good results, but rather intractable diplopia. Hence, the therapist has to consider key differential diagnostic factors in order to deal with the strabismus abnormalities that can be solved aiming to establish functional vision. Also, fusion is the ultimate and final goal of a vision therapy programme. According to Press (1997), “Brock did not accept the patient for treatment, if he believed that the patient could not possess the capacity to achieve fusion”. Fusion is a differential diagnostic factor when examining the patient for the first time, because if the patient possesses this capacity even in specific position of gaze and preferably in Randot stereo test, then the optometrist may be able to bring out the optimal VT result of functional binocular vision.

A generic sequential programme of vision therapy for children with strabismus and normal retinal correspondence would initially include activities focusing on antisuppression, ocular motility, accommodation, convergence and divergence, peripheral awareness and fusion, monocular, MFBF and later biocular and binocular activities to achieve fusion. If strabismus is the first diagnosis and another dysfunction is present and detected as secondary, such as accommodative insufficiency, then activities that focus on the improvement of accommodative facility and amplitude, such as monocular loose lens rock, Hart chart, aperture rule, Brock string can also be included in the primary care of strabismus [14].

Older studies which describe orthoptic treatment techniques lack the holistic approach of today’s vision therapy procedures. Guibor’s 1934 and McGillivray’s 1942 reviews focus mainly on the procedures of overcoming suppression and re-aligning the eyes by achieving only a degree of fusion. The antisuppression techniques of these studies are based on increasing illumination before the suppressed eye, using coloured filters and prism slip-overs causing diplopia. The recommendation of the authors on the binocular macular perception and stereopsis enhancement is to use the Weels, Sattler and Guibor charts. In addition to this, the synoptophore and fusion targets increase the fusion amplitude [15,16]. Lundlam’s review in 1961 comes closer to modern techniques and philosophy of vision therapy encompassing ocular motility, eye-hand coordination, accommodative, convergence and fusion training [17]. Currently, other authors, such as Cook and Press, focus the vision therapy treatment on peripheral fusion and monocular fixation in a binocular field techniques. At the initial stage of therapy of strabismus these techniques are useful stepping stones in improving peripheral awareness. The same authors emphasise that antisuppression and Brock string techniques shouldn’t be used if diplopia is considered to become intractable [18,19]. Press, in his book, commences the therapy by integrating procedures of body movement, such as the alternate side creeping utilising hands and knees with right and left stickers and calling out “right” and “left” in conjunction with the movement, angels in the snow, games such as “Therapist says” and Marsden ball with visuomotor control stick. As the therapy progresses, the treatment shifts towards monocular training which is the steppingstone for MFBF activities, such as bimanual chalkboard circles, Wayne-saccadic fixator, Sherman VT playing cards, anaglyphic tracing and Macular Integrity Tester (MIT). The next phase incorporates biocular therapy focusing on balancing the two eyes as much as possible. Biocular exercises include anaglyphic TV trainer, Pierce light, Kraskin-Squinchel technique, antisuppression, amblyoscope, pola-mirror and visà- vis. At the final stage are the binocular treatment techniques which include the mirror superimposition in space, cheiroscopic projection in-instrument, Brock string/physiological diplopia, expansion and integration of binocular vision. Vision therapy in adult strabismic cases with normal retinal correspondence includes antisuppression, convergence, divergence, fusional vergence and computer orthoptics techniques [20]. A different approach in therapy is necessary when abnormal retinal correspondence is present. Leonard Press in his book “Applied concepts in Vision Therapy” mentions the following procedures: single oblique mirror stereoscope-macular integrity trainer (MIT), anaglyphic projection, Flom swing technique and binasal occlusion.

Strabismus treatment programmes of vision therapy differ between children and adults, according to Leonard Press in his book “Applied concepts of Vision Therapy” who includes a separate section with specific therapy activities for young children. These are: abduction calisthenics, afterimages, the Lindsay puppet board, Black fanner board/anaglyphic checkers, luster matching, happy face tracking and diplopia on the run. At a first glance, most of these activities seem like a simple game exercise, yet their purpose is to practice the missing visual skills in an individual’s strabismic case and reduce the symptoms of the strabismus visual dysfunction. Young children find it often difficult maintaining attention and focus for long periods of time. It is very helpful when the therapist demonstrates a variety of exercises in his quiver by which the child does not lose interest in the process. The engagement of a child’s attention plays a significant factor in the efficacy of VT treatment. Moreover, it is equally important that the activities in a VT programme shall relate to the cognitive level of the child. Adult patients are able to maintain attention on activities that do not look as fun as those in children. The communication between the therapist and an adult patient may differ from that with a child; for example, an adult patient with previous visual experiences may be more capable in describing the visual changes that occur during an exercise. Needless to say, this is not the rule in every adult and child case, as many are the times when the communication between a small child and a therapist is excellent. However, a therapy programme of a strabismic adult patient is important to be executed with caution, careful consideration of the involved activities and thorough diagnostic optometric evaluation. If abnormal retinal correspondence (ARC) is present in the strabismic eye, antisuppression activities may lead to intractable diplopia. Hence, before commencing a VT programme, a complete optometric evaluation provides necessary information regarding the visual problems and abnormalities related to the strabismus of the individual, thus helping the therapist design a taylor-made VT treatment programme that will encounter the visual dysfunctions and suit the visual needs of the patient. Finally, the following treatment procedures are recommended by the author of this review. Specifically, binasal occlusion is very helpful as an initial step in “breaking” an esotropic deviation and potential cross-fixation. Binasals enhance the peripheral awareness of the strabismic eye in far and close distances. Furthermore, in cases where normal retinal correspondence is present, antisuppression techniques may be incorporated into the therapy programme, whereas the same techniques must be completely avoided in patients with abnormal retinal correspondence. When ARC is deeply rooted into the visual system and the individual presents fusion abilities using the new point on the retina, then the best option would be to amplify the ARC point of fusion. An effort to “erase” the new retinal focus point utilising antisuppression techniques may lead to intractable diplopia. As mentioned before, the enhancement of the ARC retinal point of the strabismic eye along with the NRC retinal point of the non-strabismic eye, helps to maintain fusion and avoid intractable diplopia.

VT procedures shall also include binocular peripheral awareness combined with binasal occlusion, eye movement exercises using gross targets and engaging saccades and pursuits and MFBF activities which are the stepping stone for biocular and binocular procedures. At the final stage there are the biocular and binocular activities where fusion is practiced and enhanced.

Conclusion

Strabismus demonstrates a polymorphy of symptoms of visual dysfunctions, such as amblyopia, suppression, abnormal retinal correspondence, nystagmus, absence of stereopsis and vergence and eye movement abnormalities. The collection of data studied from different reviews in strabismic animals and humans present the alteration that occurs in areas in the brain that control binocular fusion and eye movements. Areas in V1 present deficits in neural synapses and connections, binocular ocular dominant columns and demonstrate abnormalities in layer 4 which is responsible for stereoscopic vision. Oculomotor areas such as the superior colliculus and the cerebellum which both control the eye movements and nystagmus respectively and extrastriate visual areas in the “dorsal” and “ventral” stream and the vestibulo-ocular reflex are also affected.

Vision therapy procedures applied in different strabismic cases indicate that a part or even full binocular fusion and stereopsis may be recovered along with the orthoptic alignment of the eyes. A variety of combination of VT activities is recommended by different authors depending on the age of onset, the diagnostic factors, the cognitive capacity of the patient and the cooperation with the therapist. Furthermore, VT procedures are different in infants, whose therapy is passive, rather than in children and adults. As far as the differences in VT procedures in children from 6 ~ 7 years of age and adults is concerned, a similar approach is observed by the different authors, yet with minor variations not only in the order of activities, but also in incorporating other exercises. Moreover, different VT procedures apply in both adults and children, when other abnormalities, such as amblyopia and abnormal retinal correspondence co-exist along with the strabismus problem. VT activities must be carefully selected when intractable diplopia is considered to be a possible result. Hopefully, more research in the neural mechanisms and causes of strabismus, vision therapy procedures and studies investigating the changes in the affected brain areas before and after vision therapy, shall occur in the future. This will pave the way for better understanding both the strabismus problem and the influence of VT treatment in the brain.

Read more about Lupine Publishers Journal of Trends in Ophthalmology click on the below link:

https://ophthalmology-lupine-publishers.blogspot.com/



Wednesday, 12 July 2023

Lupine Publishers | Ophthalmic Manifestations of COVID-19 and its Association with Heparan Sulfate Receptors

 Lupine Publishers | Trends in Ophthalmology Open Access Journal


Abstract

Coronavirus disease-2019 (COVID-19) caused by a novel enveloped, positive sense, single stranded RNA virus called Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) started originally in Wuhan, China. By March 2020, the disease was declared a global pandemic as the virus spread to all major countries in the world. Initially, it was believed that the virus was transmitted through inhalation of respiratory droplets from an infected person. But given the exponential increase in the number of infected people, more modes of transmission were explored. While all possible routes of transmission of this virus are still undetermined many studies implicate the eyes as the initial site of infection and conjunctivitis as an early symptom of COVID-19. In this review, we summarize various studies that suggest SARS-CoV-2’s presence on ocular surfaces and that the eyes can be a gateway for transfer of SARS-CoV-2 to the extraocular sites including the lungs. We also explore the role of heparan sulfate, a newly discovered co-receptor for the virus in ocular manifestations.

Keywords: SARS-CoV-2; COVID-19; Ocular; Heparan Sulfate; ACE 2; Conjunctivitis

Introduction

Coronaviruses (CoV) are a large family of enveloped RNA viruses. Structurally, a typical virion consists of envelope proteins and spike proteins protruding from its envelope surrounding the nucleocapsid. The spike proteins play an important role in binding to host cells. These viruses cause severe respiratory and enteric infections in humans as well as animals. A newly discovered strain, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is responsible for the ongoing global outbreak of coronavirus disease 2019 (COVID‐19) [1]. Initially pneumonia, cough and respiratory problems were the only reported symptoms for COVID-19 [2]. But there have been many reports of inflammation and irritation of eye in COVID-19 patients. While conjunctivitis or pink eye has not been established as an official symptom for COVID-19, few studies indicate it as an ocular manifestation of SARS-CoV-2 infection [3, 4]. To provide some history, a study conducted during the 2003 Severe Acute Respiratory Syndrome (SARS) outbreak detected SARS-CoV in tear samples of SARS patients in Singapore [5]. Insufficient eye protective equipment was considered to be one of the reasons for SARS-CoV transmission, indicating a concern that respiratory illness could be transmitted through ocular secretions [6,7]. Similar alarming situations have been raised with SARS-CoV-2 especially amongst the healthcare professionals involved with eye care and the healthcare workers present in the triage area and involved with checking symptoms of the patients and sample collection [8]. This also puts ophthalmologists and other healthcare workers at risk who are examining the COVID-19 patients manifesting conjunctivitis. An Ophthalmologist, Li Wenliang, MD died because of COVID-19. The source of transmission of the virus was later found out to be an asymptomatic glaucoma patient who visited his clinic [8]. COVID-19 is normally believed to be transmitted by respiratory droplets [9]. However, some growing body of evidence links conjunctivitis to the early stages of COVID-19 infection [4]. The ocular surface might also act as a point of entry and facilitate coronavirus transmission. Thus, to combat a global threat like COVID-19 with many asymptomatic patients, it is imperative to understand these other unexplored pathways for infection and the underlying mechanisms.

SARS CoV-2 Host Cell Entry

SARS-CoV-2 entry into the host cell is mediated via its spike glycoprotein S. The spike uses angiotensin-converting enzyme 2 (ACE2) as its receptor on host cells to facilitate the infection as a primary receptor [10]. SARS-CoV-2 spike protein binds with both cell surface heparan sulfate receptor and angiotensin-converting enzyme 2 (ACE2) by binding with its receptor-binding domain (RBD). Docking studies suggest a heparin/heparan sulfate-binding site adjacent to the ACE2-binding site. Both ACE2 and heparin can bind independently to spike protein in vitro, and a ternary complex can be generated using heparin as a scaffold. Electron micrographs of spike protein suggest that heparin enhances the open conformation of the RBD that binds ACE2. On cells, spike protein binding depends on both heparan sulfate and ACE2 [11]. In a study conducted by Wan and co-workers, it has been shown that the S glycoprotein of SARS-CoV-2 has a receptor binding domain (RBD) and the residue 394 (Glutamine) is responsible for binding with ACE2 receptors [12]. The S glycoprotein is activated by proteolytic cleavage by transmembrane serine protease (TMPRSS2) or the protease Furin (also known as Paired Basic Amino Acid Cleaving Enzyme) for interaction with ACE2 [13]. In TMPRSS2-negative cells, the cysteine proteases cathepsin B/L can facilitate S protein cleavage [14]. Furin acts by cleaving S1 subunit of spike protein which leads to conformational changes in S2 subunit of the spike protein. These changes expose the membrane proteins needed for virus to fuse with membrane to enter the cell as represented in Figure 1[13]. Certain human coronaviruses like HCoV-NL63 need co-receptor such as heparan sulphate (HS) in addition to ACE on host cell membrane for the virus to bind and facilitate its entry into the host cell. HS has also been indicated to play an important role in SARS-CoV’s ability to infect [15]. Studies show reduction in heparin or heparinase leads to decrease in SARS-CoV entry in cells [16]. SARS-CoV-2 displays conformational changes during binding of the virus RBD and the host cell heparan sulphate [17].

Figure 1: SARS-CoV and SARS-CoV 2 viruses enter the host cell by interacting with ACE 2 and heparan sulfate. Cell surface protease TMPRSS2 and Furin activates the SARS-CoV virus entry.

Lupinepublishers-openaccess-ophthalmology-journal

Ocular Viral Transmission

Globally, governments are trying to impose different preventative measures to contain COVID-19. All nations are employing nationwide lockdowns, but epidemiologic data indicate differences in disease incidence. Some countries have been successful in flattening the curve whereas even after stay at home orders, the cases are exponentially rising in some other countries. This points towards an incomplete understanding of the modes of transmission. Several studies suggest transmission modes through aerosols and fomites especially given the high transmissibility rate and some molecular characteristics of the virus [18]. Thus, to reduce disease transmission, it is necessary to research into all possible ways of disease transmission.

Previous studies have demonstrated that the mucosa of the ocular surface and respiratory tract express identical receptors for certain respiratory viruses [19-22]. On the basis of the epidemiological information from earlier Coronavirus infections, various theories have been anticipated such as:

a) The conjunctiva can act as a site of direct inoculation by droplets containing virus particles.

b) The nasolacrimal duct acts as a route of virus infection to the upper respiratory tract.

c) Haematogenic (from blood) infection of the lacrimal glands [23].

In case of SARS-CoV-2, also a respiratory virus, interaction of its spike protein with host ACE2 is responsible for viral entry as well as human-to-human transmission [9,10]. Thus, the expression of receptor ACE2 on the surface of corneal epithelium and conjunctival epithelial tissues indicates a plausible role of eye in COVID-19 transmission. But the level of ACE2 expression observed in the ocular tissues was found to be much lower than the respiratory and kidney tissues [17]. Also, the binding ability of SARS-CoV spike protein to the ACE2 expressed on the ocular surfaces was observed to be weaker than the binding ability with the ACE2 receptors on the surface of Vero E6 cells in-vitro and the lung tissues in-vivo [20].

In this review, we suggest ocular transmission in addition to transmission by respiratory droplets, fomites and aerosols as a mode of SARS-CoV-2 transmission. Respiratory viral infections leading to development of ocular symptoms have been previously documented [4]. Scientists have hypothesized a model for eye as a gateway to transmission of virus to the respiratory tract. According to the anatomy, the mucosa of the conjunctiva and corneal epithelium and the upper respiratory tract are connected by the nasolacrimal duct [19]. When a drop of liquid is inserted into the eye the liquid is partially absorbed by the cornea and conjunctiva but mostly is passed into the nasal cavity through nasolacrimal duct and then transported to the upper respiratory tract including pharynx and trachea or else it can be taken to the gastrointestinal tract as shown in Figure 2 [24]. This ocular surface to systemic transmission hypothesis originally proposed by Belser has been further corroborated by viral inoculations of adenoviruses and influenza viruses in the cornea of animal models including mice, rats and rabbits. And presence of viral loads in tear samples from these animals have been detected [19]. CoVs can result in a wide spectrum of ocular infections in animals. The conjunctival swabs of 90% cats infected with feline CoV (FCoV) had the FCoV antigen. This indicates the probability of ocular manifestations of SARSCoV- 2 in patients similar to the CoVs of animals [25]. The potential of infection through ocular secretions is currently unknown, and it remains unclear how SARS-CoV-2 accumulates in ocular secretions. Possible theories include direct inoculation of the ocular tissues from respiratory droplets or aerosolized viral particles, migration from the nasopharynx via the nasolacrimal duct, or even hematogenous spread through the lacrimal gland [26].

Figure 2: Transfer of SARS-CoV 2 from the eyes to the lungs occurs via nasolacrimal system. Respiratory droplets containing SARS virus weakly attach to HS and ACE 2 on the epithelial lining of the cornea. Due to lower affinity interactions with its receptors on the corneal surface, the virus, in most cases, fails to enter the ocular cells and it is released in the tear fluid, which is then absorbed by the lacrimal duct and the virus is transported to the nose and then the lungs

Lupinepublishers-openaccess-ophthalmology-journal

Conjunctivitis and Its Correlation with Coronavirus

Conjunctivitis (pink eye) is inflammation of the transparent membrane that lines the eyelid (conjunctiva) due to infections or allergies. The symptoms are watery, itchy red eyes with crusting around the eyes [27]. Many viruses can cause conjunctivitis. Unlike antibiotic eye drops for conjunctivitis caused by bacteria, viral conjunctivitis is self-healing [4]. Viral conjunctivitis is caused by DNA viruses like adenoviruses or herpesviruses and RNA viruses like picornavirus and HIV. Thus, conjunctivitis is a common ocular manifestation observed with many viruses [4]. During previous coronavirus outbreaks like SARS-CoV and HCoV-NL63, Real-time Reverse transcription polymerase chain reaction (rRT-PCR) in tears have detected the presence of virus [28, 29]. But many reports for SARS‐CoV or MERS‐CoV do not recognize conjunctivitis as a sign or symptom [30]. For NL63 infections, a review combined 15 studies with almost 7,000,000 patients and conjunctivitis was reported in only 17 % of one study of 300 patients [15]. Additionally, some strains of coronavirus infections displayed no viruses in their tears. Considering the history of viruses and many human case studies for SARS-CoV-2, there is a growing interest among researchers to study ocular manifestation of coronaviruses.

Animal studies

Animal studies can help to better understand the effects of coronavirus on eye after infecting the eye with coronavirus.

Animal models and infection techniques to study specifically ocular manifestation of SARS-CoV has not been established yet. Studies for other types of coronaviruses, however, have been established. There are severe ocular manifestations due to coronaviruses in cats and mice like anterior uveitis, retinitis, vasculitis, and optic neuritis [25]. One non-peer reviewed article compared the effects of SARSCoV- 2 infection in different anatomical sites in rhesus monkey – eye (conjunctiva), lungs (trachea) and stomach. Monkeys that were only injected via trachea experienced weight loss. After 24 hours of infection, viral RNA was detected only in conjunctival swabs of monkeys infected via the eyes. These monkeys also had mild lung infection. For the infection via trachea, there was presence of SARSCoV- 2 RNA in the nasal and throat swabs of the monkey [31]. This animal study sheds light on the significance of site of manifestation of infection being related to the transmission route of the infection. Thus, using experimental designs from previous coronavirus animal models, more studies need to be conducted to understand ocular transmission and manifestation of SAR-CoV-2. Histology studies should be performed on infected eye to completely understand these ocular manifestations.

Standardization of techniques needed for detection of viral conjunctivitis

It has been observed that viral conjunctivitis is caused by direct inoculation of the virus in the conjunctiva for animal models. Different COVID-19 patients seem to have variations in the conjunctivitis manifestations. One patient with COVID-19 had viral RNA in conjunctival swabs taken just after two days of infection, whereas another patient displayed bilateral conjunctivitis for 21 days after the infection. Another case study report had a COVID-19 patient with conjunctivitis but with no viral RNA in tears [32]. These studies show the diversification and differences in these ocular manifestations patient to patient. Thus, more sensitive techniques need to be adapted to track virus induced conjunctivitis for more accurate data. Different instruments have been used to analyze or detect viral RNA in patients. One study collected tear using a Schirmer strip and analyzed viral RNA in tears by rRT-PCR. They collected samples for 3 weeks from the onset of infection [26]. In this study, one patient had conjunctivitis and viral RNA was detected in tears. Another study used swab to collect conjunctival secretions from lower fornix of the eye [33]. They also collected tear data from the lower fornix. In some other studies, tear samples were collected from lower fornix and conjunctival scraping from lower palpebral conjunctiva. The eyelids were everted and then the lower fornixes were swiped with sterile cotton swabs to collect the samples. No topical anesthesia was given. Another study collected tears randomly on nine days and 19.4 days after infection [5]. While three positive cases were found in the 9-day cohort, negative results were observed in 19.4 days sample set. The available data shows very low number of cases having ocular manifestations of COVID-19. Additionally, the tear or conjunctival swab samples tested positive for SARS-CoV-2 in a single study was not significant. Therefore, a more standardized method for detection of SARSCoV- 2 in tear samples is required. By testing of large number of samples a data can be generated to provide better understanding of ocular manifestation of COVID-19. Masaki Imai et al., suggest that Syrian hamsters are susceptible to SARS-CoV-2 replicating efficiently in lungs and causing severe pathological lesions [34]. They also reported that SARS-CoV-2 can replicate in the brain or olfactory bulb of hamsters but failed to detect viral antigens in these regions. Chan et al. also demonstrated use of Syrian hamster model for SARS-CoV-2 transmission studies [35].

Human case studies

In case of the ongoing pandemic COVID-19, there have been multiple reports of conjunctivitis during initial stages of the infection. Recently, a woman with COVID-19 was reported to have unilateral conjunctivitis with other symptoms like cough and nasal congestion. Her initial diagnosis was presumed to be herpetic keratoconjunctivitis. Antiviral treatment for herpes had no effect in reducing the symptoms and the unilateral conjunctivitis remained for seven days. She was tested positive for SARS-CoV-2 after seven days. The laboratory diagnosis revealed the patient was weakly positive for SARS-CoV-2 and was found negative for other secondary bacterial infections [36]. There was another similar case where the patient initially diagnosed with conjunctivitis, reported fever symptoms two days later. On testing, the patient was found to be SARS-CoV-2 positive [37]. On January 22, 2020, a Chinese respiratory specialist who visited Wuhan as a member of the national expert panel on pneumonia claimed that he was infected by SARS-CoV-2 despite being fully gowned with a protective suit and N95 respirator. His first clinical manifestation was unilateral conjunctivitis, followed by fever and catarrhal symptoms 2 or 3 h later. It was postulated that SARS-CoV-2 probably first infected the conjunctiva, then spread and caused viral pneumonia [38]. However, in an another study by Zhou and colleagues, it was reported that conjunctivitis was identified only in one patient out of 63 COVID-19 cases and 4 suspected COVID-19 cases. Conjunctivitis was also the first symptom of SARS-CoV-2 infection in this patient. However, RT-PCR in conjunctival swab samples was positive for SARS-CoV-2 RNA from only one COVID-19 patient without conjunctivitis. This patient had no ocular symptoms. SARS-CoV-2 RNA was not detected in conjunctival swab in another similar case study of an anesthesiologist with COVID-19 and conjunctivitis. Her ocular symptoms occurred soon after performing tracheal intubation for a patient who was confirmed as having COVID-19 later, and this was followed by fever and cough. Unfortunately, the personal protections used by this anesthesiologist during the tracheal intubation procedures were only a surgical mask, cap, and gloves, without a gown, face shield or goggles. Her five colleagues were also infected by the same patient, yet none of them exhibited any ocular complications [39]. Zhang and colleagues, reported conjunctivitis in two patients out of 72 laboratory-confirmed COVID-19 cases; however, SARS-CoV-2 was detected in conjunctival swab samples by rRT-PCR in only one patient who was a nurse working in the Emergency Department. This patient presented with excessive tearing and redness in both eyes, which were typical ocular manifestations of viral conjunctivitis, accompanied by a moderate fever of 38.2 °C that occurred 1 day earlier. SARS-CoV-2 rRT-PCR tests for the conjunctival and oropharyngeal swabs sampled 2 days after the onset of fever was positive, but for those sampled 9, 18, and 20 days after the onset of fever were all negative [40]. Xia and colleagues reported unilateral conjunctivitis in one patient out of 30 confirmed COVID-19 cases; conjunctival swabs sampled from this patient 3 and 5 days after the onset of COVID-19 were both positive for SARS-CoV-2 by rRT-PCR, whereas 58 conjunctival swab samples from the other 29 COVID-19 patients were all negative for SARS-CoV-2. However, SARS-CoV-2 was not isolated and cultured in the conjunctival swab samples from the COVID-19 patient with conjunctivitis. In contrast, 55 of the 60 sputum samples from 30 COVID-19 cases showed positive rRT-PCR results for SARS-CoV-2 [41].

Meta analytical studies

Although, ocular manifestations of COVID-19 in form of conjunctivitis are overall rare in the published literature. Only 9 (0.8%) out of 1,099 patients from 552 hospitals across 30 provinces in China were reported to have “conjunctival congestion.” [42]. A recent case series reported ocular symptoms in 12 (31.6%) of 38 hospitalized patients with COVID-19 in Hubei province, China [43]. These patients had conjunctival hyperemia (3 patients), chemosis (7 patients), epiphora (7 patients), or increased secretions (7 patients). Of note is that one patient who had epiphora presented with epiphora as the first symptom of COVID-19. Of those with ocular manifestations, 2 (16.7%) patients had positive results of SARS-CoV-2 on rRT-PCR by a conjunctival swab as well as by nasopharyngeal swabs. Only one patient in this study presented with conjunctivitis as the first symptom. The authors noted that patients with ocular symptoms had higher white blood cell and neutrophil counts, C-reactive protein, and higher levels of procalcitonin and lactate dehydrogenase compared to patients without ocular abnormalities [43]. Similarly, in an another cross sectional study, out of 535 patients, 27 patients (5.0%) showed congestion in conjunctiva and 4 patients showed conjunctival congestion as the early symptom. The mean time period of conjunctival congestion was 5.9 ± 4.5 days [SD]. The other ocular symptoms, including increased conjunctival secretion, ocular pain, photophobia, dry eye and tearing, were also found in patients with conjunctival congestion. Notably, hand–eye contact was independently correlated with conjunctival congestion in COVID‐19 patients. We also found that some COVID‐19 patients had chronic eye diseases, including conjunctivitis (33, 6.2%), xerophthalmia (24, 4.5%) and keratitis (14, 2.6%). Similar to the published studies, the most common clinical symptoms were fever, cough and fatigue. A total of 343 patients (64.1%) had positive SARS‐CoV‐2 detection in nasopharyngeal swabs [44].

In a comparison of the interaction between the animal-tohuman transmitted coronaviruses (SARS-CoV-1, SARS-CoV-2, MERS-CoV, CoV-229E, NL63, OC43, HKU1) and the eye by Sharif et al., the limit for detection of viral RNA in ocular discharge was 0–8% for SARS-CoV-1 and 0–5.3% for SARS-CoV-2, while no reports were found for other coronaviruses. Ocular manifestations have been encountered for NL63 and SARS-CoV-2. Ocular clinical symptoms in the form of conjunctivitis/conjunctival congestion were mainly detected in 65 (3.17%) out of 2048 reported patients with COVID-19 (range of 0.8–32%). Eye symptoms were not reported for the other coronaviruses [45].

On 20th Mar 2020, Sarma, et al. screened 5 different literature databases (PubMed, Google Scholar, EMBASE, Medrixv, and BioRixv). In their systematic review and meta-Analysis, authors included studies about the ocular manifestation of SARS-COV-2 patients were without language restriction. This study concluded that 3.17% of patients show ocular manifestation. However, only 1.949% of patients show tear/conjunctival swab RT-PCR positivity. However, in spite of presence of the virus in the ocular fluid, only 33.3% showed sign of conjunctivitis/conjunctival chemosis or red eye. Again vice versa, i.e. among patients with COVID-19 associated conjunctivitis/red eye, only 28.65% showed evidence of presence of the virus in ocular fluid [46]. Loffredo et al. evaluated the frequency of conjunctivitis in patients affected by severe and non-severe COVID-19 infection according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) only on clinical studies identified by searching Pubmed, ISI Web of Science, SCOPUS, and Cochrane electronic databases. On 5th Apr 2020, authors included 1,167 COVID-19 patients in their metaanalysis. The rate of conjunctivitis was 1.1%; it was 3% and 0.7% in severe and nonsevere COVID‐19 patients, respectively. The metaanalysis showed that patients with severe COVID‐19 infection had, at admission to the hospital, increased incidence of conjunctivitis (odds ratio: 3.4; 95% confidence interval:1.1‐10.2; P = .030) [47].

Siedlecki, et al. used the PubMed.gov for searching relevant articles. On 16th Apr 2020, authors identified 21 articles on the ophthalmological aspects of COVID-19 were identified. Of these, 12 (57.1%) were from Asia, 6 (28.6%) were from the United States of America, and 3 (14.3%) were from Europe. There were 5 (23.8%) original studies, 10 (47.6%) letters, 3 (14.2%) case reports, and 3 (14.2%) reviews [48]. On 29th May 2020, Emparan et al. published a structured review on COVID-19 and ophthalmology using PubMed, ScienceDirect, LILACS, SciELO, the Cochrane Library, and Google Scholar as electronic databases. The Oxford Center for Evidence- Based Medicine 2011 Levels of Evidence worksheet was employed by authors for quality assessments. More than 1,000 manuscripts were identified in the research; only 26 records were included in the qualitative synthesis and of these only 17 were classified as level 5 within the classification system of the Oxford CBME methodology, the rest were level 4 [49]. Lastly, on 16th Jun 2020, Torres-Costa et al. reviewed the most relevant articles together with the official recommendations of ophthalmological societies by literature search on PubMed electronic database [50]. Investigations have revealed that highly infectious human CoVs (mainly SARS-CoV and SARS-CoV-2) are rarely detected by rRT-PCR and never isolated by virus culture in tears and conjunctival secretions from SARS and COVID-19 patients. Hence, it is hard to assess the infectivity of tears and conjunctival secretions and their roles in virus transmission [38-51].

Receptors Involved in Ocular Manifestations

It has been observed that SARS-CoV-2 : has a stronger binding affinity towards ACE2 in comparison to SARS-CoV due to differences in the spike protein gene. ACE2 is the receptor required for SARS-CoV-2 entry into the host and is expressed in conjunctival epithelial cells and corneal cells and tissues [52]. Although expression of ACE2 in eye is much less than that in heart, lung tissues and Vero E6 cells. In cornea, expression of mRNA for ACE2 has also been reported. This mRNA expression in cornea is lower in comparison to testes, small intestine and heart [52]. As discussed TMPRSS2 or Furin which are required to activate spike protein are not found in corneal epithelium or conjunctival cells. The average mRNA expression for TMPRSS2 in these corneal cells is around 0.6 % which is usually in the range 1.2-1.4 % in tissues like lung parenchyma, heart and nasal cavity [52]. In a study conducted by Zhou and coworkers, various eye specimens were tested for expression of ACE2. Across all eye specimens, immunohistochemical analysis revealed expression of ACE2 in the conjunctiva, limbus, and cornea, with especially prominent staining in the superficial conjunctival and corneal epithelial surface. Surgical conjunctival specimens also showed expression of ACE2 in the conjunctival epithelium, especially prominent in the superficial epithelium, as well as weak or focal expression in the substantia propria. All eye and conjunctival specimens also expressed TMPRSS2. These results suggest that ocular surface cells including conjunctiva are susceptible to infection by SARS-CoV-2, and could therefore serve as a portal of entry as well as a reservoir for person-to-person transmission of this virus. This highlights the importance of safety practices including face masks and ocular contact precautions in preventing the spread of COVID-19 disease [39]. On the other hand, in a study conducted by Ma and coworkers, rRT-PCR analysis showed consistent expression by 2 ACE2 gene primers in 2 out of 3 human conjunctival cells and pterygium cell lines. Expression by 2 TMPRSS2 gene primers could only be found in 1 out of 3 pterygium cell lines, but not in any conjunctival cells [53]. Compared with the lung A549 cells, similar expression was noted in conjunctival and pterygium cells. In addition, mouse cornea had comparable expression of TMPRSS2 gene and lower but prominent ACE2 gene expression compared with the lung tissue. Considering the necessity of both ACE2 and TMPRSS2 for SARSCoV- 2 infection, the results suggest that conjunctiva would be less likely to be infected by SARS-CoV-2, whereas pterygium possesses some possibility of SARS-CoV-2 infection. The cornea has shown higher level of expression of ACE2 and TMPRSS2 than conjunctiva. Hence, the cornea has higher potential to be infected by SARSCoV- 2 [53].

Other receptors expressed in human corneal and conjunctival cells that can bind to SARS-CoV-2 are CD209 (on corneal dendritic cells) and CD26 (vascular endothelial cells), CD13, 9‐O‐acetylated sialic acid and heparan sulfate (HS). These receptors usually found in human tears act as binding site for coronaviruses. SARS-CoV binds to CD209 and CD26 [32, 54]. Human CoV-229E binds to CD13 for cell infection. HKU-1 binds to 9‐O‐acetylated sialic acid [55]. NL63 binds to ACE-2 by initial attachment to HS before binding to ACE2 [15]. But this binding alone does not cause an infection. HS has been previously indicated to help in viral attachment in addition to ACE2 for many viruses. But the presence of lactoferrin on ocular surface can prevent this binding to HS. This data suggest that coronaviruses might weakly bind to ocular surfaces but may not necessarily cause an infection especially due to lack of proteases TMPRSS2 or Furin [32].

Role of Heparan sulfate in Ophthalmic manifestation of COVID-19

The receptors intercellular adhesion molecules – 1 (ICAM-1) or αvβ3 and αvβ6 integrin facilitate conformational changes in virus after the initial binding during viral conjunctivitis. The other host receptors low density lipoprotein (LDL) and heparan sulfate proteoglycan (HSPG) also aid in viral endocytosis. For many other viruses HSPG is known to enhance viral binding [4]. Studies have revealed that the invasion of SARS-CoV and HCoV-NL63 into host cells not only relies on the presence of ACE2 on host cell membrane as an entry receptor but also is modulated by other factors on host cell membranes such as HSPG, which serves as an attachment receptor [15, 56].

Heparan Sulfate

HS is a complex carbohydrate. It has sulfate residues attached at oxygen and nitrogen sites [57]. HS is ubiquitously expressed on the surfaces and in the extracellular matrix of virtually all cell types, making it an ideal receptor for viral infection [58]. It occurs in the form of proteoglycan HSPG in which two or three HS chains are attached in close proximity to cell surface or extracellular matrix protein [59,60]. A complex biosynthetic process is responsible for the production and modification of HS, which takes place through coordinated action of several glycosyltransferases and sulfotransferases. HS is composed of repeating disaccharide units of glucosamine and uronic acid, with variable additions of sulfate groups and other modifications. As a result of its high sulfation, HS has an extreme negative charge density, and thereby binds with a large variety of extracellular ligands, including growth factors, cytokines, and enzymes [61]. HS has been known for many years to serve as a major attachment receptor for many human viruses, including dengue virus, hepatitis C virus, human immunodeficiency virus, human papilloma virus, and essentially all herpes viruses [62-64]. In this form, the HS binds to a variety of protein ligand and help in the regulation of various biological functions including developmental process, angiogenesis (Formation of new blood vessels), coagulation of blood, antagonists for Granzyme B and also acts as receptor for various viral infections including SARS-CoV-2 [65-66]. HS is known for interacting with different proteins to regulate and facilitate cell adhesion, the cell cycle, and inflammation. As previously mentioned, many viruses need HS as a co-receptor for entry into the host [57].

Role in virus attachment

To demonstrate the interaction between SARS-CoV-2 spike protein and HS receptor, a study was conducted by Liu and coworkers [17]. In this study, a HS oligosaccharide library showed the spike of SARS-CoV-2 can bind HS in a length- and sequence-dependent manner. A controlled HS synthesis was used for production of attached sulfate residues in different lengths with varied patterns and numbers. It is believed that different cells express specific HS binding sites to attract the HS specifically needed to regulate a metabolic process. In many other proteins, this preferential binding to certain repeating pattern of oligosaccharides has been observed. Liu and coworkers screened a different HS library with varying and different patterned chains and studied viral binding to each specific HS molecule. They also used cell culture and drosophila model to study spike protein and RBD binding of the virus respectively. They have identified two types of HS molecules having greater affinity towards spike protein of SARS-CoV-2. Hexaand octasaccharides composed of IdoA2S-GlcNS6S repeating units were identified as optimal ligands. Surface plasma Surface Plasmon Resonance (SPR) showed the SARS-CoV-2 spike protein binds with higher affinity to heparin (KD 55 nM) compared to the RBD (KD 1 μM) alone [17]. An octa-saccharide composed of IdoA2S-GlcNS6S could inhibit spike-heparin interaction with an IC50 of 38 nM. The data supports a model in which the RBD of the spike of SARS-CoV-2 confers sequence specificity for HS expressed by target cells [17]. An additional HS binding site in the S1/S2 proteolytic cleavage site enhances the avidity of binding. Glycosaminoglycan (GAG) binding motif at S1/S2 proteolytic cleavage site on spike glycoprotein may facilitate novel coronavirus (SARS-CoV-2) host cell entry [67]. In a study conducted by Kim and coworkers, three GAG-binding motifs were identified. Site 1 in S1 region 453-459 (YRLFRKS), site 2 at S1/S2 proteolytic cleavage site 2681-686 (PRRARS), and site 3 at S2 region 810-816 (SKPSKRS) Figure 3. The binding of the three sites were studied using a surface plasmon resonance direct binding assay, it was found that both monomeric and trimeric SARSCoV- 2 spike more tightly bind to immobilized heparin than the SARS-CoV and MERS-CoV. Later in the same study using unbiased computational ligand docking indicated that HS interacts with the GAG binding motif at the S1/S2 site on each monomer interface in the trimeric SARS-CoV-2 S glycoprotein, and at another site (453- 459 (YRLFRKS)) when the RBD is in an open conformation [17, 67]. The three dimensional structure of the spike protein along with the HS binding domains have been shown in the Figure 4.

Figure 3: SARS-CoV-2, Spike glycoprotein Heparan sulfate: (a) Site 1 in S1 region 453-459 (YRLFRKS); (b) Site 2 at S1/S2 proteolytic cleavage site 2681-686 (PRRARS), and (c) site 3 at S2 region 810-816 (SKPSKRS) binding highlighted in box.

Lupinepublishers-openaccess-ophthalmology-journal

Figure 4: The SARS-CoV-2 spike protein structure showing heparan sulfate binding domain: (a) 453-459 (amino acids YRLFRKS) colored in red; (b) Close up view of the heparan sulfate receptor binding, highlighting domain 453 – 459 (amino acids YRLFRKS) motif at the surface of the domain colored in red. (c) S2 region 810-816 (SKPSKRS) colored in red; (d) Close up view of the heparan sulfate receptor binding highlighting domain 810 - 816 (amino acids SKPSKRS) motif at the surface of the domain colored in red; (e) RGD domain S gene 403 – 405 colored in red; (f) Close up view of the heparan sulfate receptor binding, highlighting domain 403 – 405 (amino acids RGD) motif at the surface of the domain colored in red.

Lupinepublishers-openaccess-ophthalmology-journal

The RBD undergoes conformational change upon interaction with low molecular weight heparins [68]. SARS-CoV-2 S1 RBD binds to heparin and that upon binding, a significant structural change is induced. Moreover, moieties of basic amino acid residues, known to constitute heparin binding domains, are solvent accessible on the SARS-CoV-2 S1 RBD surface and form a continuous patch that is suitable for heparin binding [59]. The dependence of the host on the interaction of hundreds of extracellular proteins with the cell surface GAG molecules for the regulation of homeostasis is exploited by many microbial pathogens as a means of adherence and invasion. The closely related polysaccharide heparin, a widely used anticoagulant drug, which is structurally similar to HS and is a common experimental proxy, can be expected to mimic the properties of HS. Heparin prevents infection by a range of viruses when added exogenously, including S-associated coronavirus strain HSR1 and inhibits cellular invasion by SARS-CoV-2 [59]. It has been previously demonstrated that unfractionated heparin binds to the Spike (S1) protein RBD, induces a conformational change and have reported the structural features of heparin on which this interaction depends. Furthermore, it is demonstrated that enoxaparin, a low molecular weight clinical anticoagulant, also binds the S1 RBD protein and induces conformational change [59]. SARS-CoV-2 uses integrins as cell receptors in one or more host species, binding to them through a conserved RGD (403–405: Arg-Gly-Asp) motif that is present in the RBD of the spike proteins of all SARS-CoV-2 sequences analyzed to date [Figure 5]. The motif was identified by a PROSITE scan that included motifs with a high probability of occurrence (PDOC00016) Table 1 [60].

Table 1: Amino acid moieties responsible for binding of Heparan sulfate receptors with S glycoprotein of SARS-CoV-2.

Lupinepublishers-openaccess-ophthalmology-journal

Figure 5: SARS-CoV-2, Spike glycoprotein Heparan sulfate binding RGD (403-405) domain highlighted in box.

Lupinepublishers-openaccess-ophthalmology-journal

Targeting Heparan Sulfate for Therapeutic Applications

This review indicated the possibility of Heparan sulfate as playing a significant role in viral entry. Different mechanisms have been suggested over the year to block heparan sulfate to prevent viral binding. These inhibitors can help prevent ocular transmission of the viral particles.

Fibroblast growth factor-2 (FGF-2):

FGF is a strong heparin binding protein. Previous studies have indicated that stromal keratitis caused by ocular herpes virus infection can be diminished by FGF-2. FGF-2 competes with HSV-1 for heparin sulfate [69]. This role of FGF-2 in inhibiting binding of virus and heparin sulfate in ocular surfaces can be extended to treat spread of SARS-CoV 2 through ocular surfaces.

G1 and G2 peptide

G1 and G2 are peptides developed against commercially found HS and specifically modified 3-OS HS respectively. [70]. A phage display peptide library screening method was used to find these peptides to block against HS. This strategy of developing peptides showed promising results as a therapeutic against ocular HSV-1 infection in mouse corneas with no damage to the corneal epithelium. [70] Thus, these peptides might also show promise against ACE2 binding to HS in human corneas for SARS-CoV-2 treatment.

Inhibition by Heparin

Heparin belongs to family of GAG molecules. In humans, heparin is produced exclusively by mast cells and stored there in granules. Mast cells are located in the lungs, gut and along the blood vessels and heparin from these mast cells plays an important role in host defense mechanism. Heparin competes with HS for adhesion of bacteria and viruses and thus inhibits the invasion by pathogen [71]. Heparin can be used to inhibit cellular invasion by SARS-CoV-2 by interaction of the surface protein (spike) S1 RBD with heparin [68]. Studies have also shown inhibition of SARS-CoV-2 entry by bovine Lactoferrin- another HS mimic [72]. Nebulization of heparin for use as therapeutic against SARS-CoV-2 is another promising option [73]. Unfractionated heparin inhibited spike protein binding with an IC50 value of <0.05U/ml. This suggests that heparin, particularly unfractionated forms, could be considered to reduce clinical manifestations of COVID-19 by inhibiting continuing viral infection [16]. Administration of low-molecular-weight heparin is beneficial to patients with severe coronavirus disease 2019 (COVID-19), but the mechanism is unknown. HS may bind to severe acute respiratory syndrome coronavirus 2 spike protein to block viral attachment or entry. HS attenuates inflammation responses through neutralizing the activity of pro-inflammatory proteins, that is, histone and high mobility. Use of specially designed HS oligosaccharides offer a new strategy to manage COVID-19 [17]. Although there are no studies for using heparin at ocular surface for COVID-19, further studies in animal corneas can be used to promote Heparin to block HS for SARS-CoV-2 entry into eyes.

Most severe manifestations of COVID‐19 cases, such as multiple organ failure and death, have been linked to coagulation dysfunction markers, such as platelet reduction and increases in prothrombin time, fibrin degradation products, and, mainly, D‐dimer [74]. A recent paper by Tang et al in this journal reported that heparin treatment reduced mortality of COVID‐19 patients with elevated Ddimer; similar preliminary results have been reported elsewhere [75, 76]. A mounting body of evidence shows that SARS‐CoV‐2 causes a “cytokine storm” that activates the coagulation cascade, leading to thrombosis [77]. Similar to the findings in severe sepsis, generalized deposition of intravascular thrombi compromises the blood supply of several organs, leading to organ failure [78]. A direct anticoagulant effect is likely crucial to the therapeutic effect of heparin, it also has antiarrhythmic properties that shows promise in the treatment of COVID‐19, in which cardiac arrhythmias are the immediate cause of several patient deaths [79]. Heparin had been used in 1734 patients. Heparin was associated with lower mortality when the model was adjusted for age and gender, with OR (95% CI) 0.55 (0.37–0.82) p=0.003. This association remained significant when saturation of oxygen<90%, and temperature>37 °C were added to de model with OR 0.54 (0.36–0.82) p=0.003, and also when all the other drugs were included as covariates OR 0.42 (0.26–0.66) p<0.001. The association between heparin and lower mortality observed in the study by Ayerbe et al can be acknowledged by clinicians in hospitals and in the community [80]. In an another clinical study conducted by Shi et al the D-dimer, C reactive protein CRP and PBMC (peripheral blood mono-nuclear cells percentage, IL-6 and other parameters was analyzed in patients with low molecular weight heparin (LMWH) treatment and control group. Under conventional antiviral treatment regimens, LMWH can improve hypercoagulability, inhibit IL-6 release, and counteract IL-6 biological activity in patients. LMWH has potential antiviral effects and can help delay or block inflammatory cytokine storms. It can also increase the lymphocytes (LYM%) of patients and has the potential for treatment of COVID-19 [81]. As per our literature search, no concrete data is available on the ocular therapeutic usage of these molecules/drugs. Only limited studies have been done in relation to ocular manifestation of COVID-19.

GAG mimetics

Synthetic GAG mimetics are polyanionic molecules that inhibit HS-protein interactions. Heparin polysaccharides are digested to generate GAG derivatives. Heparin are good inhibitors too and have been able to prevent binding of viruses like HSV [82] and HPV [64]. But it’s anticoagulant characteristics induce thrombocytopenia. To overcome these problems, GAG mimetics were developed. Examples of GAG derivatives that have been developed are non-sulfated K5 polysaccharide from E. coli and 3-O-sulfated octasaccharide which is like 3-O-sulfate domain of HS. These have been successful in blocking viral infections. Blocking H5N1 influenza virus attachment by modified heparin mimetics showed promising results. Desuflation of this modified heparin reduced the anticoagulant effect without hampering the inhibition. Other potent antiviral GAG mimetics with effective viral inhibitions are rhamnan sulfate, PG545, and PI-88. Sulfated polysaccharides similar to HS isolated from seaweed have been effective in inhibiting HSV virus and Dengue. GAG derivatives are promising as antiviral in cell cultures. In vivo testing in corneas is required to use these as antiviral for humans in future. PI-88 and PG545 were in clinical trials for treating tumors. But due to its toxic effects, the trial was discontinued [83]. Better and safer GAG derivatives directed towards ocular surfaces might have potential as a SARS-CoV 2 antiviral for ocular manifestation.

Discussion

There is an increasing number of scientific reports regarding conjunctivitis as an ocular manifestation of COVID-19. Given the history of coronaviruses found in tears or conjunctival swabs, scientists believe that SAR-CoV-2 should also display a similar phenomenon. Many institutes are trying to collect more data to corroborate this theory. Although growing number of publications are reporting ocular manifestation case studies, the data with coronavirus patients with conjunctivitis is still rare. The presence of various viral receptors on the ocular surface such as ACE2 and HS do indicate the probability of ocular transmission of Covid-19, but the actual human data is limited in number and scope to support this theory. The relatively weaker binding of ACE2 on ocular surface indicates that the virus may only transiently stay there during an early infection and then move to the nasolacrimal duct via the tear fluid to reach the lungs where it binds strongly to the cells expressing ACE2 and HS to facilitate the infection and subsequently, the respiratory disorders. The data till now indicates that understanding these ocular manifestations are secondary in priority. However, with this epidemic growing, each piece of information is important to find possible treatment and prevent its transmission.

Acknowledgement

This work was supported by NIH grants (R01 EY024710 and P30 EY001792) to D.S.

Conflict of Interest

There is no economic interest or conflict of interest.


Read More About Lupine Publishers Journal of Trends in Ophthalmology Click on the below link:

https://ophthalmology-lupine-publishers.blogspot.com/